


Form PTO-1595 (Rev. 6/93) OMB No. 0651-0011 (exp. 4/94)		RECORDATION FORM COVER SHEET U.S. DEPARTMENT OF COMMERCE PATENTS ONLY Patent And Trademark Office	
To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.			
1. Name of conveying party(ies): <u>Kionix, Inc.</u> Additional name(s) of conveying party(ies) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		2. Name and address of receiving party(ies): Name: <u>Advion Biosciences, Inc.</u> Internal Address: _____ _____ _____ 3. Street Address: <u>15 Catherwood Road</u> _____ City: <u>Ithaca</u> State: <u>New York</u> Zip: <u>14850</u> Additional name(s) & addresses attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
4. Nature of conveyance: <input type="checkbox"/> Assignment <input type="checkbox"/> Merger <input type="checkbox"/> Security Agreement <input type="checkbox"/> Change of Name <input checked="" type="checkbox"/> Other <u>license</u> Execution Date: <u>October 17, 2003</u>		5. Application number(s) or patent number(s): If this document is being filed together with a new application, the filing date of the application is: _____ A. Patent Application No.(s) _____ B. Patent No.(s) <u>6,432,311</u> Additional numbers attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
6. Name and address of party to whom correspondence concerning document should be mailed: Name: <u>Patent Group</u> Internal Address: <u>Foley Hoag LLP</u> _____ _____ Street Address: <u>155 Seaport Boulevard</u> _____ City: <u>Boston</u> State: <u>MA</u> ZIP: <u>02210</u>		7. Total number of applications and patents involved (1) _____ 8. Total Fee (37 CFR 3.14) \$ <u>40.00</u> <input type="checkbox"/> Enclosed <input checked="" type="checkbox"/> Authorized to be charged to our deposit account 9. Deposit account number: <u>06-1448, Ref. 23983-6; KNX-5 DV4</u> (Attach duplicate copy of this page if paying by deposit account)	
DO NOT USE THIS SPACE			
10. Statement and signature. <i>To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the redacted version of the original document.</i> <div style="display: flex; justify-content: space-between;"> <div style="width: 30%;"> <u>Kingsley L. Taft, Reg. No. 43,946</u> Name of Person Signing and Reg. No. </div> <div style="width: 30%; text-align: center;">  Signature </div> <div style="width: 30%; text-align: right;"> <u>November 18, 2003</u> Date </div> </div>			
Total number of pages including cover sheet, attachments, and document: (5)			

Mail documents to be recorded with required cover sheet information to:
 Commissioner of Patents & Trademarks, Box Assignments
 Washington, D.C. 20231

RECORDAL FORM OF LICENSE AGREEMENT

ADVION BIOSCIENCES, INC., a Delaware Corporation with its principal place of business at 15 Catherwood Road, Ithaca, New York ("Advion"), and KIONIX, INC., a Delaware corporation with its principal place of business at 36 Thornwood Drive, Ithaca, New York ("Kionix"), have entered into a Licensed Agreement, dated October 17, 2003, pursuant to which, among other things, Kionix has granted certain rights to Advion that are exclusive and non-exclusive in nature. A redacted copy of certain provisions of the License Agreement are provided below:

* * *

License Agreement

THIS LICENSE AGREEMENT (referred to herein as this "License" or this "Agreement"), dated as of October 17, 2003 (the "Effective Date"), is made by and between ADVION BIOSCIENCES, INC., a Delaware Corporation with its principal place of business at 15 Catherwood Road, Ithaca, New York ("Advion"), and KIONIX, INC., a Delaware corporation with its principal place of business at 36 Thornwood Drive, Ithaca, New York ("Kionix"), each of Advion and Kionix referred to as a "Party" and collectively as the "Parties" herein.

ARTICLE I – DEFINITIONS

1.1 "Affiliate" means any entity that controls, is controlled by, or is under common control with a Party hereto. For purposes of this definition, "control" means (a) in the case of corporate entities, direct or indirect ownership of a majority of the stock or shares having the right to vote for the election of directors, and (b) in the case of non-corporate entities, direct or indirect ownership of a majority of the equity interest with the power to direct the management and policies of such non-corporate entities, *provided however* that if local law restricts foreign ownership, with respect to each of the immediately preceding clauses (a) and (b), control shall be established by direct or indirect ownership of the maximum ownership percentage that may, under such local law, be owned by foreign interests.

1.4 "Exclusive Field of Use" means the manufacture, use, sale, offer for sale and import of an electrospray device for use in connection with mass spectrometry. Said electrospray device may, or may not, further contain fluid manipulation structure(s) (e.g., ports, channels, reservoirs, valves) and/or separation science technology(ies) (e.g., liquid chromatography, high performance liquid chromatography, capillary electrophoresis, capillary electrochromatography (CEC), solid-phase extraction (SPE), liquid-liquid extraction, affinity techniques), but said fluid manipulation structure(s) and/or separation science technology(ies) by themselves are not within the Exclusive Field of Use.

1.7 "Licensed Patent Rights" means (a) U.S. Application Serial No. 09/156,037 (the "'037 Application"), U.S. Application Serial No. 09/156,507 (the "'507 Application"), and U.S. Application Serial No. 60/122,972 (the "'972 Application"), and (b) all Patent Rights, filed for before or after the Effective Date, with the right of priority based in whole or in part, directly or indirectly, on the '037 Application, the '507 Application and/or the '972 Application, other

than the '145 Patent Rights. **EXHIBIT A** sets forth the Licensed Patent Rights in existence as of the Effective Date

1.12 "Patent Rights" means (a) any patents, patent applications, any patents issuing therefrom worldwide, and all provisional rights with respect to patent applications, (b) any substitutions, divisions, continuations, continuations-in-part, reissues, renewals, registrations, confirmations, re-examinations, extensions, supplementary protection certificates, term extensions (under applicable patent law or regulation or other law or regulation), and certificates of invention of any patents or patent applications, and (c) any foreign or international equivalents of any of the foregoing.

1.18 "third party" means any entity or person other than Advion or Kionix.

ARTICLE II – LICENSES

2.1 License to Licensed Patent Rights.

2.1.1 Kionix hereby grants to Advion a worldwide, perpetual and irrevocable license, under all of Kionix's entire right, title and interest in and to the Licensed Patent Rights, to make, have made, use, import, offer for sale and sell any products, services and methods, *both in and outside* the Exclusive Field of Use. The license granted by this Section 2.1.1 is not exclusive, except as expressly set forth in Section 2.2.

2.2 Exclusivity of License to Advion. The license granted by Kionix in Section 2.1.1 shall be exclusive to Advion within the Exclusive Field of Use with respect to all persons and entities other than Advion (*i.e.*, Kionix, all its Affiliates and all third parties). During the term of this Agreement, Kionix shall not (a) utilize or practice, or grant any rights of any kind to any Kionix Affiliate or any third party, with respect to the Licensed Patent Rights within the Exclusive Field of Use

2.5 Sublicenses. ... The license granted by Kionix in Section 2.1.1 shall be sublicensable by Advion through multiple tiers to third parties without the consent of Kionix, *but only* in the Exclusive Field of Use.

3.1.2

(A) ... the U.S. patent application identified in **EXHIBIT C** as 200701/1008 and having U.S. Serial No. 10/427,145 (the "**'145 Application**"). ... (a) the '145 Application, (b) all Patent Rights issuing thereon or otherwise arising therefrom, and (c) all claims of Patent Rights with the right of priority based in whole or in part, directly or indirectly, on the '145 Application, provided such claims encompass only the inventions or aspects thereof claimed as of the Effective Date in the '145 Application (all of the foregoing Patent Rights identified in the immediately preceding clauses (a) to (c), the "**'145 Patent Rights**").


* * *


LICENSE AGREEMENT

IN WITNESS WHEREOF, the Parties hereto have executed this Agreement effective as of the Effective Date.

ADVION BIOSCIENCES, INC.

KIONIX, INC.

By 
Thomas R. Kurz
Chief Operating Officer

By 
Gregory J. Galvin, Ph.D.
President and CEO

PATENT

REEL: 014128 FRAME: 0845

Redacted Exhibit A

U.S. Patent Application No. 09/745,779 issued as Patent No. 6,432,311